Cargos activos de Terry O’Neal
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
jCyte, Inc.
jCyte, Inc. Medical/Nursing ServicesHealth Services jCyte, Inc. engages in the provision of retinal therapies. Its therapy focuses with retinitis pigmentosa, and retinal progenitor cells. The company was founded by Terry O?Neal, Henry Klassen and Jing Yang in 2012 and is headquartered in Newport Beach, CA. | Director Administrativo | 01/07/2020 | - |
Fundador | 01/01/2012 | - | |
Director de Operaciones | 01/01/2012 | 01/07/2020 | |
Ray Therapeutics, Inc.
Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Director de Operaciones | - | - |
Historial de carrera de Terry O’Neal
Estadísticas
Internacional
Estados Unidos | 3 |
Operativa
Chief Operating Officer | 2 |
Chief Administrative Officer | 1 |
Founder | 1 |
Sectorial
Health Services | 2 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
jCyte, Inc.
jCyte, Inc. Medical/Nursing ServicesHealth Services jCyte, Inc. engages in the provision of retinal therapies. Its therapy focuses with retinitis pigmentosa, and retinal progenitor cells. The company was founded by Terry O?Neal, Henry Klassen and Jing Yang in 2012 and is headquartered in Newport Beach, CA. | Health Services |
Ray Therapeutics, Inc.
Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Commercial Services |
- Bolsa de valores
- Insiders
- Terry O’Neal
- Experiencia